Osteoarthritis of knee
Methodology & AI Transparency ⓘ
Osteoarthritis of knee Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Designated in federal medical registries as M17.9, Osteoarthritis of knee falls under Arthritis & Joints management, where topical/targeted anti-inflammatory therapy [Osteoarthritis of knee M17.9] establishes baseline severity and rules out diagnostic mimics.
- 2 Real-world patient consensus: Diagnostic registry M17.9: Osteoarthritis of knee is managed within Arthritis & Joints.
- 3 Typical cash cost range: Workup highlights for Osteoarthritis of knee (M17.9): topical/targeted anti-inflammatory therapy [Osteoarthritis of knee M17.9].
- 4 Top reported side effects / signs: Objective lab/clinical target for Osteoarthritis of knee: Weight-Bearing Joint Radiograph [Osteoarthritis of knee M17.9] (Preserved joint-space width (M17.9)) and Serum Uric Acid in Osteoarthritis of knee (M17.9: (Gout Target)).
Ask our AI Specialists anything about Osteoarthritis of knee
What Is Osteoarthritis of knee?
Designated in federal medical registries as M17.9, Osteoarthritis of knee falls under Arthritis & Joints management, where topical/targeted anti-inflammatory therapy [Osteoarthritis of knee M17.9] establishes baseline severity and rules out diagnostic mimics.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in arthritis & joints, Osteoarthritis of knee (M17.9) involves monosodium urate or in Osteoarthritis of knee (M17.9: calcium pyrophosphate crystal). progression correlates with shifts in Weight-Bearing Joint Radiograph [Osteoarthritis of knee M17.9] (Preserved joint-space width (M17.9)).
Common Symptoms & Clinical Signs
- • Presentation of Osteoarthritis of knee (M17.9): brief morning joint in Osteoarthritis of knee (M17.9: stiffness)
- • Secondary Osteoarthritis of knee clinical sign: sudden, intensely painful, in Osteoarthritis of knee (M17.9: red swollen big-toe)
- • Symptom flares in Osteoarthritis of knee correlating with Weight-Bearing Joint Radiograph [Osteoarthritis of knee M17.9] deviation outside Preserved joint-space width (M17.9)
- • Functional arthritis & joints impact requiring topical/targeted anti-inflammatory therapy [Osteoarthritis of knee M17.9] evaluation (M17.9)
Osteoarthritis of knee Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | M17.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Osteoarthritis, Gout & Joint Pain | NLM Clinical Tables |
| Diagnostic / Lab Marker: Weight-Bearing Joint Radiograph [Osteoarthritis of knee M17.9] | Preserved joint-space width (M17.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Uric Acid in Osteoarthritis of knee (M17.9: (Gout Target)) | < 6.0 mg/dL (< 5.0 mg/dL with tophi) (M17.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: hs-CRP & Erythrocyte in Osteoarthritis of knee (M17.9: Sedimentation Rate) | hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M17.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Osteoarthritis of knee
Treatment selection for Osteoarthritis of knee depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Osteoarthritis of knee)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Exercise Type and Duration on Pain, Function, and Quality of Life in Patients: What a 3,808-Participant Study Found J Orthop Sports Phys Ther 2026;56(11):724-734. The Journal of orthopaedic and sports physical therapy • 2026-11-15 • Meta-Analysis | N = 3,808 | 94/100 | PMID 42966901 ↗ |
| New Insights on A single intra-articular injection of JTA-004, a combination of human plasma,: What a 746-Participant Study Found A single IA injection of JTA-004 was not superior to a saline solution (LSmean difference: -1.50 mm, 95%CI 5.12; 2.12, p= 0.42) or Synvisc-One® (LSmean difference: 2.40, 95% CI: -1.22; 6.02, p=0.20) for the treatment of OA... Osteoarthritis and cartilage • 2026-02-15 • Phase III Randomized Trial | N = 746 | 93/100 | PMID 41015076 ↗ |
| New Insights on A Phase 3, 28-week, multicentre, randomised, gold-standard blind, compared: What a 498-Participant Study Found LOR was well tolerated despite not meeting the primary endpoint. Clinical and experimental rheumatology • 2025-05-15 • Phase III Randomized Trial | N = 498 | 93/100 | PMID 39808288 ↗ |
| New Insights on A Phase 3, 56-week, randomised, gold-standard blind, compared against a dummy: What a 513-Participant Study Found 513 patients were randomised. Clinical and experimental rheumatology • 2025-05-15 • Phase III Randomized Trial | N = 513 | 93/100 | PMID 39808286 ↗ |
| New Insights on Efficacy of duloxetine for multisite pain in patients with knee pain due to: What a 353-Participant Study Found These results are consistent with duloxetine enhancing the activity of descending inhibitory pain pathways that are dysfunctional in patients with central sensitization and multisite pain. Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association • 2021-01-15 • Phase III Randomized Trial | N = 353 | 93/100 | PMID 32245696 ↗ |
Osteoarthritis of knee Patient Community & “People Like Me” Threads
Filter Osteoarthritis of knee community threads and patient logs by age, biological sex, dosage, and treatment duration.